1. Park2 gene mutation in parkinson patients

Nguyen Tien Lam, Pham Le Anh Tuan, Tran Tin Nghia, Le Thi Phuong, Nguyen Hoang Viet, Bui Tran Tuyet Nhi, Tran Huy Thinh, Tran Van Khanh

Main Article Content

Abstract

PARK2 gene encodes parkin protein, functions as an E3 ubiquitin ligase. PARK2 mutations are among the main causes of familial chromosomal Parkinson's disease, characterized by early onset (before 50 years of age). Mutations in the PARK2 gene segment account for about 9.5% - 14% of patients with early onset. This study aims to identify deletion mutations on the PARK2 gene in Parkinson's patients and family members. In a study conducted on 30 Parkinson's patients with an average age of 51.47 ± 11.91 years old, male/female ratio of 1.3, we found that 4/30 patients (13.3%) carried mutations in the PARK2 gene segment differentiated by MLPA technique. This study shows practical implications for patients and contributes to the Parkinson's disease database as well as genetic consultation for family members.

Article Details

References

1. Rui Q, Ni H, Li D, Gao R, Chen G. The Role of LRRK2 in Neurodegeneration of Parkinson Disease. Current neuropharmacology. 2018; 16(9): 1348-1357. doi:10.2174/1570159x16666180222165418.
2. Houlden H, Singleton AB. The genetics and neuropathology of Parkinson’s disease. Acta neuropathologica. Sep 2012; 124(3): 325-38. doi:10.1007/s00401-012-1013-5.
3. Chu MK, Kim WC, Choi JM, et al. Analysis of dosage mutation in PARK2 among Korean patients with early-onset or familial Parkinson’s disease. J Clin Neurol. 2014; 10(3): 244-248. doi:10.3988/JCN.2014.10.3.244.
4. Lücking CB, Dürr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denèfle P, Wood NW, Agid Y, Brice A; French Parkinson’s Disease Genetics Study Group; European Consortium on Genetic Susceptibility in Parkinson’s Disease. Association between early-onset Parkinson’s disease and mutations in the parkin gene. N Engl J Med. 2000 May 25; 342(21): 1560-7. doi: 10.1056/NEJM200005253422103. PMID: 10824074.
5. VCV000813338.5 – ClinVar – NCBI. Accessed April 26, 2022. https://www.ncbi.nlm.nih.gov/clinvar/variation/813338/?new_evidence=true
6. Nhữ Đình Sơn. Nghiên cứu đặc điểm lâm sàng và một số yếu tố nguy cơ của bệnh Parkinson. 2003. Luận án tiến sĩ y học.
7. Ambroziak W, Koziorowski D, Duszyc K, Górka-Skoczylas P, Potulska-Chromik A, Sławek J, Hoffman-Zacharska D. Genomic instability in the PARK2 locus is associated with Parkinson’s disease. J Appl Genet. 2015 Nov; 56(4): 451-461. doi: 10.1007/s13353-015-0282-9. Epub 2015 Apr 2. PMID: 25833766; PMCID: PMC4617850.
8. Hedrich K, Kann M, Lanthaler AJ, Dalski A, Eskelson C, Landt O, Schwinger E, Vieregge P, Lang AE, Breakefield XO, Ozelius LJ, Pramstaller PP, Klein C. The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. Hum Mol Genet. 2001 Aug 1; 10(16): 1649-56. doi: 10.1093/hmg/10.16.1649. PMID: 11487568.
9. Koyano F, Okatsu K, Kosako H, Tamura Y, Go E, Kimura M, Kimura Y, Tsuchiya H, Yoshihara H, Hirokawa T, Endo T, Fon EA, Trempe JF, Saeki Y, Tanaka K, Matsuda N. Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature. 2014 Jun 5; 510(7503):162-6. doi: 10.1038/nature13392. Epub 2014 Jun 4. PMID: 24784582.